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Abstract The IL-1 cytokine family comprises 11 members (7
ligands with agonist activity, 3 receptor antagonists and 1 anti-
inflammatory cytokine) and is recognised as a key mediator of
inflammation and fibrosis inmultiple tissues including the lung.
IL-1 targeted therapies have been successfully employed to
treat a range of inflammatory conditions such as rheumatoid
arthritis and gouty arthritis. This review will introduce the
members of the IL-1 cytokine family, briefly discuss the cellu-
lar origins and cellular targets and provide an overview of the
role of these molecules in inflammation and fibrosis in the lung.
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Introduction
Progressive loss of organ function due to fibrosis contributes
significantly to the ever-growing burden of chronic disease in
the world. In addition, because progression in these diseases
occurs over several years, they account for enormous morbid-
ity within society, major health resource utilisation and loss of
working days and tax revenues. For example, the total cost of
respiratory disease in the 28 countries of the EU alone
amounts to more than €380 billion annually (European Lung
White Book, Chapter 2). Improving our understanding of the
processes that fail to orchestrate physiological repair in the
injured organ and instead cause pathological repair as fibrosis
will aid the identification of new therapeutic approaches that
can impact in this area.
Fibrosis causes excessive collagen and extra-cellular ma-
trix deposition in an organ or tissue as part of an attempted
reparative process following injury. It may represent an aber-
rant response to a single large injury but more commonly is a
response to a persistent or repetitive injury. The association of
fibrosis with many chronic inflammatory conditions suggests
that the beneficial reparative processes that restore tissue ho-
meostasis in physiological healing continue unchecked and
instead result in pathological damage and loss of organ func-
tion. Chronic lung disease is a very common cause of morbid-
ity and mortality across Europe, with diseases such as idio-
pathic pulmonary fibrosis (IPF) accounting for >2500 deaths a
year and chronic obstructive pulmonary disease (COPD) caus-
ing over 30,000 deaths/year in the UK with a rising incidence
(predicted to become the third common cause of death by
2020) [1, 2]. Fibrosis causes significant dysfunction of the
lung by remodelling the small airways in COPD contributing
to airflow limitation [3] and by remodelling the parenchyma in
IPF severely impairing gas exchange [4]. Both conditions are
associated with significant inflammation, yet the mechanisms
linking inflammation to fibrosis in the lung are poorly
understood.
The IL-1 family consists of 11 members, 7 of which have
been demonstrated to have broad pro-inflammatory activity
(IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β and IL-36γ)
while the remaining 4 have antagonistic (IL-1Ra, IL-36Ra,
IL-38) or anti-inflammatory (IL-37) properties. The IL-1 re-
ceptor family comprises 10 members, namely, IL-1R1, IL-
1R2, IL-1R accessory protein (IL-1RAcP), IL-18Rα, IL-
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18Rβ, ST2 (IL-33R), IL-36R (previously IL-1Rrp2), single Ig
IL-1R-related molecule (SIGIRR or TIR8), three Ig domain-
containing IL-1R related-2 (TIGIRR-2 or IL-1RAPLI) and
TIGIRR-1 (IL-1RAPL2). A simplified nomenclature for IL-
1 receptor family members (IL-1R1–IL-1R10) was recently
proposed by Garlanda et al. in Immunity [5]. The known
interactions between the IL-1 family members and the IL-1
receptor family are summarised in Fig. 1.
In this review, I will introduce the members of the IL-1
cytokine family, briefly discuss the cellular origins and cellu-
lar targets and provide an overview of the role of these mole-
cules in inflammation and fibrosis in the lung. Where appro-
priate, readers will be directed to more substantial reviews that
focus on specific topics in more detail. Additionally, although
the IL-1 cytokine family has been shown to be important in
inflammation and fibrosis in numerous organs, this review




In the 1940s, during the search for the endogenous mediator of
fever, researchers identified a small soluble candidate protein
released by activated white blood cells that was termed leuko-
cytic pyrogen [6]. In 1977, leukocytic pyrogen was purified [7]
and was demonstrated to be identical to lymphocyte activation
factor [8], a factor released from stimulated mononuclear cells
that augmented lymphocyte proliferation [9]. The term
Fig. 1 IL-1 family cytokines and their known receptors. The IL-1
cytokine family consists of seven agonists (IL-1α, IL-1β, IL-18, IL-33,
IL-36α, IL-36β and IL-36γ), three antagonists (IL-1Ra, IL-36Ra and IL-
38) and one anti-inflammatory cytokine (IL-37). The known interactions
of the IL-1 cytokines with the IL-1 receptor family are summarised above
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interleukin was introduced in 1979 to consolidate the nomen-
clature for factors with the ability to act as communication
signals between different populations of leukocytes, and the
term IL-1 was assigned to leukocytic pyrogen/lymphocyte ac-
tivation factor [10]. Several years’ later, two sequences for IL-1
cDNAwere cloned in mice and humans and were subsequently
named IL-1α and IL-1β [11, 12]. The genes for IL-1α and IL-
1β are located adjacent to one another on the long arm of
chromosome 2 and encode proteins of 271aa and 268aa
(∼31 kDa) respectively [13]. Although both proteins bind to
the same receptor (IL-1R1), triggering the recruitment of IL-
1RAcP to form a signal transducing complex [14], there are
several differences in their expression and proteolytic process-
ing that impact on their respective roles in vivo.
IL-1α is a dual-function cytokine, meaning that in addition
to functioning as a classical cytokine via cell surface receptor
ligation, full-length IL-1α can also directly regulate gene ex-
pression. For example, full-length IL-1α contains a nuclear
localisation site within its N-terminal amino acid sequence
[15] and has been shown to facilitate pro-inflammatory gene
transcription independent of IL-1R1 binding [16]. Full-length
IL-1α is constitutively expressed in the cytoplasm and nuclei of
a range of non-haematopoietic cells such as epithelial cells in a
range of tissues including the lung, liver and kidney [17].
Damage to the epithelium of the lung as a result of infection
with bacteria or virus [18, 19] or by non-infective insults such
as air pollution, oxidative stress, aspiration injury or cigarette
smoke results in the release of IL-1α from stressed/necrotic
cells into the extracellular space [20–24]. The release of IL-
1α from necrotic cells is unique as cells directed to the apopto-
tic pathway concentrate IL-1α in dense nuclear foci and there-
fore it is not released along with the cytoplasmic contents dur-
ing apoptosis [25, 26]. Full-length IL-1α, unlike full-length IL-
1β, is biologically active and functions as a damage-associated
molecular pattern (DAMP) or an ‘alarmin’ by binding to IL-
1R1 and rapidly initiating the production of chemokines and
inflammatory cytokines, driving ‘sterile inflammation’ [27,
28]. Therefore, nuclear retention of IL-1α is likely a mecha-
nism to distinguish between apoptotic and necrotic cell death
and to limit sterile inflammation in response to programmed
cell death. As well as being constitutively expressed in epithe-
lial cells, numerous other cell types have been shown to upreg-
ulate and release IL-1α in response to a range of different
stimuli including macrophages [29, 30], monocytes [31, 32]
and endothelial cells [33] among others [34].
IL-1β is an inducible cytokine and is not generally
expressed in healthy cells or tissue; however, full-length IL-
1β is rapidly induced in cells by activation of pattern recogni-
tion receptors (PRRs) such as TLRs by pathogen products or
factors released by damaged cells, leading to intracellular accu-
mulation of the protein [35]. Processing of the full-length pre-
cursor to the biologically active mature form of the protein
requires caspase-1 which cleaves the N-terminal 116 amino
acids from the precursor to generate a mature active cytokine
[36]. In the majority of cell types, caspase-1 is maintained in an
inactive state and therefore the secretion of active IL-1β is
tightly regulated. The inflammasome is a multi-protein intracel-
lular complex that is required for the conversion of pro-caspase-
1 to active caspase-1, and has been shown to be required for the
cleavage and release of mature IL-1β [37]. However,
inflammasome-independent processing of IL-1β has also been
demonstrated in caspase-1-deficient mice with neutrophil pro-
teases including elastase, proteinase-3, granzyme A, and ca-
thepsin G able to convert the IL-1β precursor to the active
mature protein extracellularly [38, 39]. Pro-IL-1β lacks an N-
terminal secretory signal or leader sequence and therefore is not
secreted via the classical endoplasmic reticulum−Golgi path-
way [40]. Despite over two decades of research, the mechanism
bywhich the active IL-1β protein is secreted from cells remains
elusive although several potential mechanisms have been pro-
posed including exocytosis of secretory lysosomes [41, 42],
microvesicle shedding from the plasma membrane [43, 44],
shedding of multivesicular bodies containing exosomes [45]
and direct efflux across hyperpermeable plasma membranes
during pyroptotic cell death [46].
Once extracellular, IL-1α and mature IL-1β bind to the IL-
1R1 to initiate downstream signalling in a range of cell types
[14]. However, additional control on the actions of IL-1α and
IL-1β at the level of receptor interactions is provided by IL-
1Ra and IL-1R2. The gene for IL-1Ra, like those encoding IL-
1α and IL-1β, is located on chromosome 2 in humans, and the
similarities in the intron–exon organisation suggests that the
IL-1Ra gene originated as a consequence of gene duplication
[47, 48]. IL-1Ra binds to IL-1R1 with comparable affinity to
IL-1α and IL-1β but fails to induce the conformational
change in the receptor that is required for the recruitment of
the IL-1RAcP co-receptor and signal transduction [49, 50].
Consequently, IL-1Ra acts as a competitive inhibitor for IL-
1R1 and completely inhibits the activity of IL-1α and IL-1β.
IL-1R2 is expressed in numerous cell types in a range of tissue
in both humans and mice [48]. Also located on chromosome
2, the gene encodes a 68-kDa (compared to the 80-kDa IL-
1R1) membrane-bound protein with a truncated (29 amino
acids) cytoplasmic tail that is lacking the TIR domain and is
therefore incapable of intracellular signalling [51]. IL-1R2 can
also be proteolytically cleaved in the proximal extracellular
region to generate a soluble receptor (sIL-1R2) [52].
Although IL-1R2 binds to IL-1α, IL-1β and IL-1Ra, the bind-
ing affinity for IL-1Ra is ∼100-fold less than for IL-1α and IL-
1β [53] and therefore IL-1R2 is likely to further enhance the
inhibitory action of IL-1Ra. For example, reducing IL-1R2
expression in keratinocyte by RNA interference increased
IL-1-mediated CCL2 and CCL5 mRNA and protein expres-
sion confirming the inhibitory effect of IL-1R2 [54].
Recombinant IL-1α and IL-1β has been shown to have
potent effects on a range of cell types in vitro, and therefore
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any unique effects attributed to IL-1α and IL-1β are likely due
to differences in the expression and/or release of the biologi-
cally active proteins rather than receptor binding or down-
stream signalling events. For example, work from our group
and others has demonstrated that fibroblasts are induced to
secrete a range of inflammatory cytokines in response to chal-
lenge with both recombinants IL-1α and IL-1β. However,
damaged lung epithelial cells release large quantities of bio-
logically active IL-1α, but little to nomature IL-1β, and there-
fore it is IL-1α that acts as the primary fibroblast stimulatory
factor in this setting [55, 56]. In contrast, peritoneal and alve-
olar macrophages have been demonstrated to regulate fibro-
blasts through the release of IL-1β, with little to no require-
ment for IL-1α [57, 58]. Both IL-1α and IL-1β have also been
shown to directly stimulate collagen synthesis and prolifera-
tion in fibroblasts [59, 60]. However, this function is contro-
versial as there is a large body of literature demonstrating an
inhibition of collagen synthesis [61, 62], and therefore further
research is required to clarify this contradiction. IL-1β has
also been shown to enhance TGF-β1-driven epithelial-to-
mesenchymal transition in vitro highlighting another potential
mode of action for the cytokine [63, 64]. However, the in vivo
relevance of epithelial to mesenchymal transition has been
challenged by a number of lineage tracing studies showing
that mesenchymal cells in fibrotic tissue do not have an epi-
thelial origin [65, 66], and therefore further research is re-
quired to establish the potential in vivo relevance of EMT-
derived mesenchymal cells in fibrosis.
Despite the aforementioned differences, both IL-1α
and IL-1β have been demonstrated to play important roles
in fibrosis in vivo. In 2001, Kolb et al. used adenoviral
gene transfer to transiently overexpress IL-1β in rat lungs
which led to an acute inflammatory response with severe
progressive tissue fibrosis [67]. Subsequently, numerous
studies have shown that administration of IL-1β can drive
a fibrotic response in the lung and that the degree of
fibrosis is of a similar magnitude to that induced by
bleomycin challenge [68, 69]. Intratracheal challenge of
wild-type mice with human recombinant IL-1α induced
neutrophilia, myeloperoxidase activity and inflammation,
all of which were abrogated in mice overexpressing IL-
1Ra [70]. Similar effects of intratracheal IL-1α challenge
were also seen in ventilated preterm lambs [71] and in rats
where IL-1α intratracheally causes an acute, neutrophil-
dependent, oxidative lung leak that closely resembles hu-
man acute lung injury [72]. Furthermore, both IL-1α and
IL-1β have been shown to be increased in mice following
bleomycin challenge and IL-1α-, IL-1β- and IL-1R1-
deficient mice are protected from bleomycin-induced pul-
monary fibrosis [55, 68]. Neutralisation of IL-1β has also
been shown to attenuate silica-induced inflammation and
fibrosis by inhibiting other inflammatory and fibrogenic
mediators and modulating the Th1/Th2 balance [73].
Mice overexpressing IL-1Ra have a reduction in the inci-
dence and severity of collagen-induced arthritis whereas mice
lacking IL-1Ra have an earlier onset of collagen-induced ar-
thritis [74]. Administration of IL-1Ra by an osmotic
minipump in mice exposed to intra-tracheal instillation of
bleomycin or silica completely prevented lung damage and
the increase in collagen deposition seen in control mice [75].
A similar inhibition of bleomycin-induced lung pathology
was seen with Anakinra [68], an IL-1 receptor antagonist used
to treat patients with rheumatoid arthritis [76]. Using both IL-
1α- and IL-1β-deficient mice and neutralising antibodies,
Botelho et al. demonstrated a novel role for IL-1α in murine
models of COPD. The authors conclusively demonstrate that
neutrophilic inflammation induced by cigarette smoke expo-
sure is IL-1α dependent, but IL-1β and caspase-1 indepen-
dent. Furthermore, the authors used bone marrow chimeric
mice to demonstrate that IL-1R1 expression on non-
hematopoietic cells is required to induce inflammation follow-
ing cigarette smoke exposure [77].
The inflammasome has also been demonstrated to be im-
portant in the pathogenesis of lung fibrosis. For example,
Gasse et al. demonstrated that mice deficient in apoptosis-
associated speck-like protein containing a CARD (ASC), an
important component of the inflammasome, have attenuated
IL-1β production and are protected from bleomycin-induced
lung fibrosis suggesting that one of the mechanisms of action
of bleomycin is via the activation of the inflammasome [68].
In a subsequent study, the authors found that uric acid was
released into the lung parenchyma following bleomycin chal-
lenge and that a reduction in uric acid levels lead to a decrease
in IL-1β production, inflammation and fibrosis [78]. The au-
thors postulated that precipitation of uric acid and the resultant
formation of monosodium urate crystals could cause mem-
brane damage to cells leading to inflammasome activation
and downstream release of IL-1β. Subsequently, the authors
demonstrated that administration of exogenous uric acid crys-
tals recapitulates lung inflammation and repair via an
inflammasome and IL-1R1-dependent pathway [78].
Asbestos and si l ica are sensed by the NLRP3
inflammasome leading to the subsequent activation and secre-
tion of active IL-1β [79, 80]. NLRP3-deficient mice demon-
strate a reduction in immune cell recruitment to the lungs and
a lower inflammatory cytokine burden in a model of asbesto-
sis inhalation [80]. Significantly, both NLRP3- and ASC-
deficient mice are protected from silica-induced collagen de-
position confirming an important role for the inflammasome
in silica-induced lung fibrosis. A recent study by dos Santos
et al. employing vimentin-deficient mice has highlighted a
novel role for vimentin in Lipopolysaccharides (LPS)-induced
caspase-1 activation and IL-1β maturation via interactions
with the NLRP3 inflammasome. The authors demonstrate that
vimentin-deficient mice are protected from asbestos- and
bleomycin-induced lung injury and fibrosis and that
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vimentin-expressing bone-marrow-derived cells are important
for bleomycin-induced activation of the NLRP3 inflammasome
and pulmonary fibrosis [81].
The potential therapeutic value of targeting IL-1α and/or
IL-1β in a range of lung diseases becomes clear when
reviewing the literature.
Development of the chronic inflammatory airway pathology
characteristic of COPD is thought to be triggered by inhalation
of noxious particles, primarily cigarette smoke which accounts
for ∼80–90 % of cases in the USA [82]. Healthy smokers have
significantly elevated levels of IL-1β in their bronchoalveolar
lavage (BAL) compared to healthy non-smokers, with IL-1β
levels correlating in a cigarette-dose-dependent manner [83].
Increased levels of IL-1β in induced sputum from patients with
stable COPD have also been reported [84], and in a subsequent
study, the number of IL-1α- and IL-1β-positive cells was
shown to be increased in biopsy samples taken from GOLD
I/II COPD patients compared to non-COPD controls. In addi-
tion, levels of IL-1α and IL-1β in sputum and lung tissue of
COPD patients are increased [22], while levels of IL-1α and
IL-1β correlated during stable disease, at the onset of exacer-
bation and post-exacerbation [77]. Uric acid, which has been
demonstrated to play an important role in lung fibrosis in mice
via an inflammasome- and IL-1R1-dependent pathway, has al-
so been reported to be elevated in BAL of healthy smokers
compared to healthy non-smokers as well as COPD patients
who smoke compared to healthy smokers [85, 86].
Furthermore, serum uric acid has been shown to be associated
with increased 30-day mortality and risk for acute exacerba-
tions and hospitalisation in COPD patients [87].
Several studies have presented evidence of activation of the
inflammasome in COPD. For example, increased caspase-1
activation was observed in lung samples from smokers and
emphysema patients, compared with non-smokers [88].
Inhibition of caspase-1 significantly reduces inflammation in
response to challenge with cigarette smoke in animal models
[89]. Various molecules that activate the inflammasome have
also been shown to be elevated in COPD patients. For exam-
ple, extracellular ATP activates the NLRP3 inflammasome by
engaging the purinergic P2X7 receptor [90], and the P2X7
receptor is upregulated on alveolar macrophages and blood
neutrophils from patients with COPD [91]. In addition, extra-
cellular ATP is elevated in BAL fluid from patients with
COPD as compared with normal control subjects and ATP
concentrations correlate with an increase in airway infiltration
and is associated with a decline in lung function [91, 92].
Together, these data suggest a role for the inflammasome in
contributing to the airway inflammation seen in COPD.
IL-1β has also been shown to be elevated in BAL and lung
biopsies from IPF patients compared to normal volunteers [69].
Furthermore, in both serum and BAL, a decreased IL-1Ra/IL-1β
ratio was found in IPF patients compared to healthy controls, and
this imbalance might contribute to a proinflammatory
environment in IPF lungs [93]. Autoantibodies against IL-1α
were detected in the sera of 11/11 rapidly progressive IPF patients
on the 21st hospital day following admission for severe symp-
toms (compared to 5/11 on the first hospital day) suggesting that
extracellular IL-1α may be an undesirable factor in fibrotic lung
diseases [94]. Alveolar macrophages isolated from patients with
asbestosis, sarcoidosis and IPF have higher levels of IL-1β
mRNA and spontaneous IL-1β secretion compared to control
subject [95, 96]. In contrast IL-1Ra release from ILD alveolar
macrophages was reduced compared to healthy controls, further
increasing the IL-1β/IL-1Ra ratio. Importantly, a high IL-1β/IL-
1Ra ratio was shown to correlate with BAL cellularity and was
associated with advanced or active disease [96]. Similar to
COPD, there is data indicating an important role for the
inflammasome in the development of IPF. For example, the ex-
pression of both NLRP3 and caspase-1 are elevated in
unstimulatedmacrophages isolated from the BAL of IPF patients
compared to controls [97]. Additionally, exogenous ATP is ele-
vated in the BAL of stable IPF patients compared to controls and
was further elevated in patients with exacerbated IPF [98].
Recently, the US FDA approved the first two drugs proven
to slow progression of IPF: pirfenidone (Esbriet by Roche)
and nintedanib (Ofev by Boehringer Ingelheim). Nintedanib
is a small molecule tyrosine kinase inhibitor while the precise
mechanism of action of pirfenidone is incompletely under-
stood. Both nintedanib and pirfenidone have been shown to
inhibit lung fibrosis in murine models, and these effects were
associated with a reduction in IL-1β levels in lung tissue [99,
100]. This inhibition of IL-1β may help to dampen the
profibrotic milieu in the lung, and improving our understand-
ing of whether this reduction in IL-1β is important for the
inhibitory action of nintedanib and pirfenidone will be ex-
tremely informative.
The primary limitation to survival after lung transplantation
is the development of bronchiolitis obliterative syndrome
(BOS), a chronic inflammatory process characterised by
fibroproliferation, deposition of extracellular matrix and oblit-
eration of the airways. Levels of IL-1Ra were elevated in
patients with BOS compared to healthy lung transplant recip-
ients and patients with acute rejection [101]. Furthermore,
work in my laboratory has demonstrated that IL-1α and IL-
1β concentrations are elevated in BAL samples acquired im-
mediately prior to BOS diagnosis compared to patient-
matched BAL samples acquired at other times following
transplant or in BAL samples acquired from stable transplant
controls [102, 103]. Further investigation of whether these
markers contribute to disease pathology or are simply markers
of disease progression is required.
IL-33 and ST2
Unlike most IL-1 family cytokines which are located on chro-
mosome 2, the gene for IL-33 is found on chromosome 9 (or
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chromosome 19 in mice) where it encodes a peptide of 270aa
corresponding to a full-length protein of ∼30 kDa [104]. The
full-length IL-33 protein contains a non-classical nuclear
localisation sequence (aa1-75 in human IL-33) and a non-
classical homeodomain-like helix-turn-helix DNA binding
domain in the same region with a chromatin binding domain
(aa40-58 in human IL-33) [105–107]. Consequently, the full-
length protein translocates to the nucleus where it has
intracrine gene regulatory functions by interacting with and
modulating the function of a number of proteins [108]. For
example, full-length IL-33 can function as a transcriptional
repressor by binding to the N-terminus of the p65 NF-
kappaB subunit, inhibiting binding of p65 to its promoter
sequence and therefore impairing transactivation of NF-
kappaB-regulated genes including IL-1 and TNF [109]. This
function is exclusive to the full-length IL-33 protein as the
mature IL-33 protein (aa110-266 in human) losses the nuclear
localisation and DNA/chromatin binding domains during pro-
teolytic processing.
Although full-length IL-33 is biologically active, cleavage
generates mature forms of IL-33 with up to 10-fold more
biologically active compared to the full-length protein [110].
It was originally proposed that, like other members of the IL-1
cytokine family, caspase-1 was responsible for cleavage of the
full-length protein to active mature forms [104]. However, the
predicted cleavage site for caspase-1 is not conserved in IL-
33, and further studies have suggested inactivation of IL-33
following maturation by caspase-1 [111]. Indeed cleavage
sites in IL-33 more closely resemble those for caspase-3 and
caspase-7, proteins activated during apoptosis, and cleavage
of full-length IL-33 by caspase-3 and caspase-7 generates bi-
ologically inactive breakdown products suggesting that IL-33
is destroyed in apoptotic cells [108, 112, 113]. However, ex-
tracellular full-length IL-33 can be matured by calpain, neu-
trophil elastase and cathepsin G to generate biologically active
forms of the protein (aa95-270, aa99-270, aa109-270) with
greater activity than the full-length IL-33 [110, 114, 115].
ST2, previously known as an orphan receptor of the IL-1
receptor family, was identified as the IL-33 receptor in 2005
[104]. Binding of IL-33 to ST2 drives a conformational
change in ST2 leading to the binding of the IL-33-ST2 dimer
to IL-1RAcP and downstream signalling via MyD88 [116,
117]. In addition to membrane-bound ST2, the ST2 gene in
humans encodes at least two additional spliced isoforms, sST2
and ST2V. Characterised by the lack of both a transmembrane
domain and an intracellular TIR domains, sST2 is released
from the cells to act as a soluble decoy receptor by sequester-
ing IL-33 and preventing its binding to membrane-bound ST2
[118]. While ST2 and sST2 are widely expressed throughout
tissues, the expression of ST2V is limited primarily to stom-
ach, small intestine and colon [119]. The exact role for ST2V
in vivo requires further investigation; however, it can be found
integrated into the plasma membrane when transfected into
COS7 cells suggesting a possible role in modifying the IL-
33-ST2 signalling complex [119].
Although the expression of IL-33 was originally thought to
be restricted to constitutive expression in a small number of
cell types including endothelial cells [120], it is now clear that
IL-33 is muchmore abundant (fibroblasts, epithelial cell, mac-
rophages, among others) and that its expression can be regu-
lated in much the same way as other members of the IL-1
family. For example, treatment with various microbial com-
ponents (for example, PolyIC–TLR3 and flagellin–TLR5) in-
creased IL-33 expression in human corneal epithelial cells
[121] and murine macrophages [122], and pro-inflammatory
cytokines including IL-3 and IL-4, and IFN-γ and TNF-α
have been shown to upregulate IL-33 in a range of murine cell
types [123] and human epidermal keratinocytes [114].
However, while it is clear that IL-33 can be upregulated and
serves many important functions in vivo, the mechanism by
which IL-33 is actively secreted from the cells is subject to
ongoing debate. What is clear is that in addition to functioning
as a classical cytokine, IL-33 can also function as an alarmin
or danger signal that is released into the extracellular space in
response to necrotic cell death or mechanical injury. For ex-
ample, full-length biologically active IL-33 can be released
from mechanically injured or damaged endothelial cells
[111]. Given that IL-33 is constitutively expressed intracellu-
larly in epithelial cells and endothelial cells in uninjured tis-
sue, it is likely to function as a very efficient alarmin in vivo.
Regardless of the mechanism leading to its release/secre-
tion, once in the extracellular environment, IL-33 has been
demonstrated to have an effect on a wide range of cell types
in a range of different organs [124]. IL-33 plays a role in type-2
immunity in response to helminth infection by driving the pro-
liferation and activation (IL-13 secretion) of innate lymphoid
cells (ILC2) leading to goblet cell hyperplasia and expulsion of
the parasite [125–127]. The IL-33-ST2 axis has also been
shown to be important in physiological remodelling of the lung
following infection with influenza virus, with blockade of IL-
33-ST2 resulting in severely decreased lung function, loss of
airway epithelial integrity and impaired tissue remodelling
[128]. IL-33-deficient mice have impaired IL-5/IL-13 secretion
from ILC2, reduced eosinophil and Th2 cell recruitment in
response to intranasal challenge with papain, a protease allergen
[129]. Dendritic cells exposed to IL-33 secrete high levels of
IL-6, TNF and IL-1β and prime naïve lymphocytes to produce
Th2 cytokines in vitro while adoptive transfer of IL-33-
activated dendritic cells exacerbates lung inflammation in an
allergy airway inflammation model [130]. Alveolar macro-
phages are polarised towards an alternatively activated pheno-
type in response to IL-33- and ST2-deficient mice have attenu-
ated ovalbumin-induced airway inflammation associated with a
decrease in AAM differentiation [131]. Several recent publica-
tions have thoroughly reviewed the role of IL-33 in tissue injury
and inflammation [124, 132, 133].
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The potential of IL-33 to have a direct effect on fibroblasts has
generated conflicting data. For example, IL-33 increases expres-
sion of both IL-6 and TNF-α expression in human keratinocytes
[134] and has been demonstrated to induced eotaxin/CCL11 pro-
duction in murine lung fibroblasts [135] and IL-6 and MCP-1
expression in murine cardiac fibroblasts [136]. However, in an-
other study, human lung epithelial cells and endothelial cells, but
not fibroblasts, were shown to express ST2 and secrete IL-8 in
response to IL-33 stimulation [137]. Further work to investigate
the IL-33-ST2 axis on fibroblasts is required.
IL-33 and ST2 have been demonstrated to play a role in
pulmonary fibrosis in vivo [138]. In response to bleomycin
challenge, mice show a substantial accumulation of IL-33-
positive cells in the lung and full-length IL-33 can potentiate
bleomycin-induced inflammation and fibrosis, potentially by
upregulating expression of TGF-β and other non-Th2 cyto-
kines [139]. A subsequent study demonstrated that intratracheal
instillation of lentivirus expressing soluble ST2 significantly
attenuated pulmonary inflammatory cell infiltration and fibrotic
changes and markedly reduced the levels of inflammatory cy-
tokines and TGF-β1 in BAL in mice challenged with
bleomycin [140]. Li et al. demonstrated that ST2-deficient mice
have attenuated bleomycin-induced lung fibrosis, and this phe-
nomenon could be recreated by IL-33 neutralising antibody
treatment [141]. Mechanistically, the authors demonstrate that
although IL-33 is constitutively expressed in epithelial cells, it
is induced in macrophages in response to bleomycin challenge
and that depletion of alveolar macrophages using clodronate
liposomes abolished both bleomycin-induced lung fibrosis
and IL-33-exacerbated lung fibrosis. IL-33 was shown to po-
larise M2 macrophages to produce IL-13 and TGF-β1 and
induced the expansion of type 2 ILC2s to produce IL-13 in
vitro and in vivo. Furthermore, ILC2s were almost completely
absent in ST2-deficient mice, and adoptive transfer of ILC2s
led to exacerbation of lung inflammation and fibrosis compared
to bleomycin challenge alone [141]. Patients with idiopathic
pulmonary fibrosis have also been reported to have elevated
levels of IL-33 in BAL and lung tissue compared to healthy
controls. Significantly, Western blotting was used to determine
the relative quantities of full-length and mature IL-33, and
higher levels of the mature, more biologically isoform of IL-
33 was seen in IPF patients [142]. In addition, serum IL-33
levels are elevated in patients with systemic sclerosis and cor-
related with the extent of skin sclerosis and the severity of
pulmonary fibrosis [143].
Expression of IL-33 and ST2 were markedly enhanced in
the lung tissue of mice challenged with cigarette smoke and
were accompanied by increased neutrophil and macrophage
infiltration and expression of inflammatory cytokines and
chemokines. Importantly, all pathological changes were atten-
uated by a neutralising anti-IL-33 antibody suggesting that IL-
33 plays a critical role in cigarette-smoke-mediated airway
inflammation [144]. A subsequent study identified that IL-
33 is expressed in bronchial endothelial cells and peripheral
blood mononuclear cells in response to cigarette smoke chal-
lenge in mice and that challenge of peripheral blood mononu-
clear cells with IL-33 enhanced cigarette-smoke-induced in-
flammatory cytokine release [145]. Kearley et al. used a com-
bination of cigarette smoke and infection to model exacerba-
tions of COPD in mice and shown that on the background of
smoke exposure, exaggerated inflammation to infection is
completely attenuated in the absence of IL-33 signalling.
Mechanistically, the authors demonstrate that cigarette smoke
upregulates epithelial-derived IL-33 and decreases ST2 ex-
pression on ILC2s while elevating ST2 expression on macro-
phages and NK cells. Consequently, upon viral infection, IL-
33 significantly amplified type I proinflammatory responses
via synergistic modulation of macrophage and NK cell func-
tion. The authors conclude that in COPD, smoke alters the
lung microenvironment to facilitate an alternative IL-33-
dependent exaggerated proinflammatory response to infec-
tion, exacerbating disease [146].
IL-33 and soluble ST2 are higher in plasma samples from
COPD patients compared to controls, and the frequency of IL-
33 expressing peripheral blood lymphocytes and neutrophils as
well as the expression of IL-33 in bronchial epithelial cells is
increased in COPD patients [147]. In another study, IL-33 ex-
pression was demonstrated to be restricted to a subset of airway
basal cells with increased capacities for pluripotency [148].
Smoking is the leading cause of COPD or COPD-related in-
flammation, and cigarette smoke extract has been shown to
accentuate the IL-33-induced expression of IL-6 and IL-8 in
human bronchial epithelial cells and PBMCs [149]. In mice,
cigarette-smoke-induced airway inflammation is characterised
by neutrophil and macrophage infiltration and increased expres-
sion of inflammatory cytokines and mucin in the airways.
Significantly, expression of IL-33 and ST2 was also increased
in response to cigarette smoke, and neutralising IL-33 inhibited
all pathogenic changes [144]. The potential of targeting IL-33 as
a therapeutic option in COPD has recently been discussed [150].
Exposure of mice to multi-walled carbon nanotubes increased
BAL total cell counts, macrophage, and neutrophil recruitment,
and increased inflammation and fibrosis located proximal to the
airways. In contrast, IL-33-deficient mice were protected from all
pathologies suggesting that IL-33 is critical for the pulmonary
toxicity induced by multi-walled carbon nanotubes [151]. IL-33
has also recently been shown to be elevated in the BAL and lung
tissue of CF patients where it has been hypothesised to be in-
volved in neutrophil recruitment [152, 153].
IL-18 subfamily
IL-18 and IL-18BP
Although originally identified in 1989 as ‘IFN-γ-inducing
factor’, IL-18 was reclassified as a member of the IL-1
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cytokine family in 1995 following purification and molecular
cloning [154]. The gene, the onlymember of the IL-1 cytokine
family to be located on chromosome 11 in humans (chromo-
some 9 in mice), encodes a full-length protein of ∼24 kDa that
is biologically inactive.Within the IL-1 cytokine family, IL-18
is most closely related to IL-1β and shares many common
traits including cleavage by caspase-1 to a biologically active
mature protein of ∼17 kDa that is actively secreted from cells
[155, 156]. Extracellular mature IL-18 binds to the alpha chain
of the IL-18 receptor (IL-18Rα) with low affinity. Binding to a
co-receptor, the beta chain of the IL-18 receptor (IL-18Rβ),
forms a high-affinity heterodimer complex with signalling ac-
tivity [157]. However, unlike IL-1α and βwhich are active on
cells in the pg/ml range, IL-18 is required in high levels of
>10 ng/ml to activate responsive cells [158–160]. In addition
to the high levels of IL-18 required to elicit a response, there
are other levels of regulation within the IL-18 signalling path-
way. For example, while IL-18Rα is expressed on numerous
cell types, the expression of the IL-18Rβ co-receptor is more
limited, being expressed on T cells and dendritic cells but not
commonly mesenchymal cells [157]. In addition, the IL-18
binding protein (IL-18BP) is a constitutively secreted protein
with very high affinity for mature IL-18 that functions by
sequestering IL-18 and therefore preventing the formation of
IL-18-IL-18R interactions [161, 162]. IL-18BP levels in the
serum of healthy individuals are in a 20-fold molar excess
[163], likely acting as a very effective regulatory mechanism.
Despite this, a role for IL-18 in many biological processes
has been reported [160, 164]. IL-18 is involved in regulation
of the Th1 response by modulating production of IFN-γ. For
example, in synergy with either IL-12 or IL-15, which
upregulates the expression of the IL-18Rβ co-receptor, IL-
18 induces the production of IFN-γ from T cells [165] and
treatment of NK cells with IL-18 induced a CD83+CCR7+
helper phenotype characterised by high ability to produce
IFN-γ [166]. Reducing IL-18 activity using IL-18 vaccina-
tion, IL-18 neutralising antibodies, IL-18BP, or performing
experiments in IL-18 deficient mice has been shown to reduce
disease severity in a number of animal models including dex-
tran sulphate sodium (DSS)-induced colitis [167, 168],
collagen-induced arthritis [169, 170] and allergic airway
hyperresponsiveness [171]. Readers are directed to the excel-
lent review by Novick et al. that further highlights the many
disease processes IL-18 and IL-18BP contribute to [160].
The role of the IL-18-IL-18R signalling pathway in fibrosis
is unclear with both pro- and anti-fibrotic effects suggested in
the literature. For example, IL-18 deficient mice were shown
to have increased mortality, lung injury, and leukocyte infil-
tration in the BAL in response to bleomycin challenge com-
pared to wild-type mice, and prophylactic treatment of wild-
type mice with IL-18 prior to bleomycin challenge reduced
lung injury and fibrosis suggesting that IL-18 plays a protec-
tive role against bleomycin-induced lung fibrosis [172].
However, a subsequent study by Hoshino et al. demonstrated
that IL-18 and IL-18Rα are elevated in the lungs of patients
with bleomycin-induced lethal lung injury and in the lungs of
mice following bleomycin challenge and that IL-18- and IL-
18Rα-deficient mice are protected from bleomycin-induced
lung fibrosis, suggesting a pro-fibrotic role for IL-18 [173].
Furthermore, overexpression of IL-18 in mice drives inflam-
matory cell accumulation (primarily CD8+ T cells, macro-
phages, neutrophils and eosinophils) resulting in severe em-
physema and airway fibrosis [174, 175]. In summary, IL-18
has been reported to have pro-fibrotic actions in vivo in the
majority of studies. In agreement with this, several studies
have demonstrated a direct effect for IL-18 on mesenchymal
cells. IL-18 enhanced the production of angiogenic factors and
key regulators of osteoclastogenesis in synovial tissue fibro-
blasts [176, 177]. Stimulation of cardiac fibroblasts with IL-18
promotes a pro-fibrotic response characterised by increased
expression of collagen I/III and periostin, increased prolifera-
tion and increased migration [178]. IL-18 levels in serum and
BAL of patients with IPF were higher than those in control
subjects, and while IL-18Rα was expressed in bronchial epi-
thelium and alveolar macrophages in control subjects, it was
found to be strongly expressed in interstitial cells, especially
the fibroblastic foci, in patients with IPF [179]. Conversely, a
recent study by Lasithiotaki et al. failed to demonstrate a dif-
ference in IL-18 levels in BAL of patients with IPF compared
to a control group but did show a significant increase in IL-18
levels in BAL of patients with rheumatoid arthritis–usual in-
terstitial pneumonia [97].
Cigarette-smoke-induced inflammation and emphysema in
the lung of wild-type mice were also associated with an in-
crease in IL-18 expression. Importantly, IL-18Rα-deficient
mice are protected from cigarette-smoke-induced inflamma-
tion and emphysema [180]. Clinically, IL-18 was shown to be
elevated in pulmonary macrophages from patients with
COPD, and levels of serum and circulating IL-18 have also
been shown to be increased in patients with COPD [180–183].
Furthermore, there is a negative correlation between serum IL-
18 level and the predicted forced expiratory volume in 1 s in
patients with COPD suggesting that overproduction of IL-18
in the lungs may be involved in disease pathogenesis [184].
IL-37
In 2000, several independent groups described IL-37 follow-
ing expression sequence tag (EST) database screening and
sequencing of the IL-1 gene cluster on human (no mouse
homologues have been described) chromosome 2
[185–188]. There are five spliced variants and isoforms of
IL-37, termed IL-37a-e, although isoform IL-37b has the most
complete set of exons and is the best characterised. IL-37 has
been shown to bind to IL-18Rα, although the affinity for the
receptor is lower than IL-18 and without any effect on IFN-γ
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production induced by IL-18 [189–191]. More recently,
SIGIRR has been shown to be indispensable for IL-37 to carry
out its anti-inflammatory effect [192]. IL-37 has also been
demonstrated to bind to the natural inhibitor of IL-18 activity,
the IL-18 binding protein (IL-18BP), leading to an enhance-
ment of IL-18BPs ability to inhibit IFN-γ production in re-
sponse to IL-18 stimulation [162, 191]. Intracellular modes of
action for IL-37 have also been demonstrated. For example,
when overexpressed in epithelial cells or macrophages, IL-37
almost completely suppressed the production of pro-
inflammatory cytokines whereas the silencing of the IL-37
gene increased the abundance of these cytokines in human
blood cells suggesting that IL-37 may possess anti-
inflammatory properties [193]. Generation of an IL-37 over-
expressing transgenic mouse has allowed the investigation of
the role of IL-37 in vivo. For example, IL-37 transgenic mice
have decreased levels of circulating cytokines, are protected
from lipopolysaccharide-induced shock and show improved
lung and kidney function as well as reduced liver damage in
response to lipopolysaccharide [193].
Mechanistically, caspase-1-mediated cleavage to the ma-
ture form of IL-37 is required for translocation to the nucleus.
In RAWmacrophages, stable transfection with IL-37 substan-
tially reduced (72–98 %) LPS-stimulated TNF-α, IL-1α and
IL-6 [194]. This inhibitory effect of IL-37 is linked to binding
to the Smad3 transcription factor as inhibition of Smad3 re-
versed the inhibition of IL-6 expression in RAWmacrophages
[195, 196]. The contribution of the IL-37-Smad3 interaction
was confirmed in vivo using IL-37 transgenic mice that had
been pretreated intranasally with siRNA specific to Smad3
prior to intranasal challenge with LPS. The reduction in cyto-
kines in the lungs in IL-37 transgenic mice was reversed fol-
lowing Smad3 knockdown [193]. IL-37 transgenic mice also
exhibited reduced clinical disease scores and histological
evidence of colitis in the DSS model of induced colitis
[197], suppressed contact hypersensitivity in response to
hapten antigen 2,4-dinitrofluorobenzene by inducing
tolerogenic dendritic cells [198] and are protected from
myocardial and hepatic ischemic damage [199, 200].
Furthermore, recombinant human IL-37 injected intraper-
itoneally into mice markedly reduced NLRP3-dependent
neutrophil recruitment and IL-1β production and mitigat-
ed lung inflammation and damage in response to intrana-
sal infection with live Aspergillus fumigatus conidia sug-
gesting that IL-37 functions as a broad spectrum inhibitor
of the innate response to infection-mediated inflammation
[201]. Excellent recent reviews further describe the anti-
inflammatory action of IL-37 [185, 202].
The CLARA childhood asthma study revealed reduced
mRNA expression of IL-37 in children with allergic asthma
and, thus, pointed toward an implication of this cytokine for
human asthma pathogenesis [203]. In addition, IL-37 levels in
serum and induced sputum were lower in asthma patients
compared to healthy controls and levels of IL-37 correlated
with disease severity suggesting a potential protective effect
[204]. A subsequent study demonstrated that IL-37 production
from PBMCs was lower in allergic asthmatic compared to
healthy children. The authors go on to demonstrate that intra-
nasal IL-37 ablated airway inflammation, mucus hyperpro-
duction and airway hyperresponsiveness in response to oval-
bumin challenge via an IL-18Rα/GIGIRR-dependent path-
way [205]. In contrast, level of plasma and serum IL-37 in
patients with active pulmonary tuberculosis was significantly
higher than that in healthy controls but recovered after treat-
ment [206, 207].Mechanistically, the authors demonstrate that
IL-37 inhibited the production of pro-inflammatory cytokines
and induced macrophages toward an M2-like phenotype
[207]. IL-37 has been shown to be increased in the bronchial
mucosa in COPD patients compared to control healthy
smokers and non-smokers [208].
Although the exact role played by IL-37 in fibrosis is yet to
be fully elucidated, it is clear that IL-37 functions as a broad-
spectrum inhibitor of the innate response to infection-
mediated inflammation and could be considered to be thera-
peutic in reducing the pulmonary damage due to non-
resolving infection and disease.
IL-36 subfamily
IL-36 and IL-36Ra
The IL-36 cytokine subfamily consists of three agonists, IL-
36α, IL-36β and IL-36γ, which bind to IL-36R (IL-1Rrp2)
and employ IL-1RAcP as a co-receptor, and a receptor antag-
onist, IL-36Ra, which binds to IL-36R to inhibit IL-1RAcP
recruitment and the formation of a functional signalling com-
plex [36, 188, 209, 210]. Although IL-1RAcP is shared with
IL-1α, IL-1β and IL-33, the IL-36R is exclusively employed
by IL-36 cytokines. Similar to other IL-1 cytokines, IL-36
cytokines require N-terminal cleavage to achieve full bioac-
tivity (∼1000–10,000-fold increase compared to non-
truncated form). Interestingly, although IL-36Ra shares 52 %
homology with IL-1Ra, the antagonistic activity of IL-36Ra is
uniquely dependent on post translational modification, specif-
ically the removal of its N-terminal methionine [211]. The
amino acid sequence at the truncation sites for IL-36 cytokines
share little homology and do not resemble classical caspase-1
cleavage sites. Moreover, no cleavage of IL-36α is observed
in bone-marrow-derived macrophages with confirmed LPS/
ATP-induced caspase-1 activation suggesting that the prote-
ase(s) responsible for cleavage of IL-36 cytokines are still to
be determined [211–213].
IL-36α, IL-36β and IL-36γ have been shown to have a
restricted expression pattern with keratinocytes, bronchial ep-
ithelial cells, brain tissue and monocytes/macrophages as the
primary sites of expression although T lymphocytes,
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peripheral blood lymphocytes and γδ T cells can also express
IL-36 cytokines in response to a range of stimuli [213–217].
Studies in Jurkat cells transfected to express IL-36R or in a
mammary epithelial cell line that naturally expresses IL-36R
(NCI/ADR-RES) demonstrated that IL-36α, IL-36β and IL-
36γ directly activate NF-kappaB [218] as well as MAPKs,
JNK and ERK1/2 leading to the downstream activation of
an IL-8 promoter reporter and the secretion of IL-6 [219].
For all molecules, blocking the IL-36R or the IL-1RAcP co-
receptor inhibited the downstream effects confirming the im-
portance of the IL-36R-IL-1RAcP complex [219].
IL-36 cytokines have also been shown to exert effects on
immune cells, particularly dendritic cells. For example, mouse
bone-marrow-derived dendritic cells upregulate key markers
of activation (CD80, CD86 andMHCII) and produce IL-6, IL-
12 and IL-23 upon stimulation with IL-36 agonists via an IL-
36R-dependent pathway [215]. IL-36 has also been demon-
strated to play a role in T cell polarisation by synergising with
IL-12 to drive the in vitro differentiation of Th0 cells into
IFN-γ+Th1 cells and to induce the production of IL-17 from
murine CD4+ cells [215, 220]. Human bronchial epithelial
cells stimulated with TNF, IL-17, IL-1β or double-stranded
(ds)-RNA upregulated the intracellular expression of IL-36α
and promoted the release of IL-36γ. Furthermore, lung fibro-
blasts were demonstrated to express IL-36R and IL-36RAcP
and stimulation of lung fibroblasts with IL-36γ leads to the
activation of MAPKs and NF-kappaB and the downstream
expression of neutrophil chemokines (IL-8, CXCL3) and
Th17 chemokines (CCL20). The data suggests that viral in-
fection and/or selected cytokines from Th17 cells or inflam-
matory cells may drive neutrophil recruitment via IL-36γ-
dependent activation of lung fibroblasts [221]. Furthermore,
challenge of human bronchial epithelial cells with infectious
agents such as Pseudomonas aeruginosa or rhinovirus has
been shown to induce the expression of IL-36γ in vitro
[222, 223], and intranasal challenge of mice with either IL-
36α or IL-36γ induces a rapid neutrophilia [224, 225]. This
data has led to the suggestion that IL-36γ released from epi-
thelial cells may contribute to neutrophil recruitment during
rhinovirus-induced exacerbation of asthma [226]. Similarly,
challenge of human bronchial epithelial cells with cigarette
smoke extract induced expression of IL-36α, IL-36β and
IL-36γ [227]. Cigarette smoke is a causative agent for
COPD, and the disease is characterised by neutrophilic accu-
mulation in the airways. It is therefore possible that IL-36
released from epithelial cells in response to cigarette smoke
challenge could contribute to the recruitment/accumulation of
neutrophils seen in patients with COPD [226, 227].
Human synovial fibroblasts express IL-36R and produce
pro-inflammatory mediators in response to stimulation with
recombinant IL-36β, albeit to a lower magnitude than other
IL-1 cytokines. In contrast, although IL-36β gene expression
was elevated in response to challenge with TNF-α and IL-1β,
the IL-36β protein was undetectable suggesting that fibro-
blasts are unlikely to be a source of IL-36β but may instead
act as responsive cells. However, similar levels of IL-36β
protein were detected in serum and synovial fluid isolated
from healthy donors and patients with rheumatoid arthritis,
osteoarthritis or septic shock, and levels of IL-36β failed to
correlate with inflammation [228]. Additionally, blocking IL-
36R or IL-36α, both found to be elevated in inflamed knee
joints of TNF-induced arthritic mice compared to wild-type
controls, had no effect on clinical onset, pattern of disease or
histological evidence of arthritis suggesting that IL-36 cyto-
kines do not affect the development of inflammatory arthritis
in vivo [229], potentially due to redundancy with other mem-
bers of the IL-1 family such as IL-1, a dominant cytokine in
rodent arthritis models [226]. Excellent reviews further de-
scribing the biology of IL-36 cytokines have recently been
published [213, 226].
There has been very little research looking at the expres-
sion of IL-36 cytokines in human disease. IL-36γ mRNA is
increased in biopsies from patients with recurrent respiratory
papillomas, and expression levels correlate with disease sever-
ity [230], and systemic IL-36α levels are decreased during
acute exacerbation episodes in patients with COPD [231].
Further investigation is required to determine the disease rel-
evance of these proteins and to identify a potential role in
fibrosis.
IL-38
IL-38 was cloned and identified as a member of the IL-1
family in 2001 [232, 233]. The IL-38 gene is located on chro-
mosome 2, between the genes encoding IL-1Ra and IL-36Ra
[234], and shares 41 and 43 % homology with IL-1Ra and IL-
36Ra respectively [233]. IL-38 is a 152-amino-acid protein
without either a signal peptide or a caspase-1 cleavage site
and is expressed in a wide range of tissues including foetal
liver, salivary glands, spleen, thymus, tonsil and skin [48, 232,
233, 235]. An initial study reported that IL-38 was able to bind
to IL-1R1, albeit with lower affinity than IL-1α, IL-1β or IL-
1Ra [232]. However, a subsequent study has identified that
IL-38 binds exclusively to IL-36R and has an antagonistic
effect similar to IL-36Ra. Specifically, the authors demonstrat-
ed thatCandida albicans-induced production of IL-22 and IL-
17 in peripheral blood mononuclear cells could be reduced by
IL-38 and that the level of reduction was similar to that
achieved with IL-36Ra [236]. IL-38 has been shown to be
elevated in the salivary glands of patients with primary
Sjögren’s syndrome, and IL-38 polymorphisms are associated
with psoriatic arthritis and ankylosing spondylitis [235, 237,
238]. However, to date, there is no literature regarding a role
for IL-38 in fibrosis, and further work is required to determine
its relevance in vivo. A recent review by Yuan et al. nicely
summarises the known roles of IL-38 [239].
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Future perspective
The complexity of the IL-1 cytokine family and the body of
literature relating to it continue to grow. In this review, I have
attempted to provide a brief overview of the current under-
standing of the IL-1 cytokine family in inflammation and fi-
brosis in the lung while highlighting some recent key obser-
vations and review articles. However, there are still numerous
outstanding questions that need to be answered. For example,
although the role of some members of the IL-1 cytokine fam-
ily in fibrosis is well established (IL-1α, IL-1β, IL-33), lead-
ing to compelling arguments for these molecules as potential
therapeutic targets, the role of others (IL-36, IL-37, IL-38)
remains to be elucidated. As we begin to understand more
about the more recently described members of the IL-1 cyto-
kine family, we are likely to identify potential new targets for
consideration as innovative therapies. Furthermore, the same
receptors can be employed by several members of the IL-1
cytokine family (for example, IL-1RAcP is shared by IL-1α,
IL-1β, IL33 and IL-36), highlighting likely redundancy.
Given the clear importance of IL-1α, IL-1β and IL-33 in lung
fibrosis and the likely compensatory action provided by mem-
bers of the IL-1 cytokine family in vivo, targeting the shared
receptors (for example, IL-1RAcP) may be more effective.
Further research to establish the potential benefits of targeting
these shared receptors or simultaneously blocking multiple
member of the IL-1 cytokine family in vivo is required.
Despite these outstanding questions, there is already a com-
pelling body of preclinical evidence to support the potential of
targeting IL-1 family cytokines in inflammatory and fibrotic
diseases, and this has resulted in a number of compounds
being evaluated as therapeutic options in a range of inflam-
matory and fibrotic diseases. Notable success has been
achieved with Anakinra in the treatment of rheumatoid arthri-
tis and other chronic inflammatory diseases such as gouty
arthritis [240] and cryopyrin-associated periodic syndrome
(CAPS) [241]. In addition, there are several compounds with
mechanism of action against IL-1 family cytokines and the
inflammasome currently under investigation in a range of dis-
eases such as P2X7 receptor antagonists (AZD9056 - 2005-
004110-32) and an anti-IL-1RI monoclonal antibody
(MEDI8968 - NCT01448850). Furthermore, there are other
IL-1α and IL-1β targeting agents such as Xilonix,
canakinumab, rilonacept, gevokizumab and AMG108 cur-
rently under investigation for other inflammatory diseases that
could also be worthwhile exploring for the treatment of chron-
ic respiratory inflammatory disorders [241, 242].
However, the slow progression of many fibrotic diseases
and the lack of early quantifiable clinical endpoints make clin-
ical trials expensive and prohibitive; therefore, the vast major-
ity of compounds described above will not be tested in pa-
tients with fibrotic lung disease. Therefore, research to identi-
fy bio-markers (sputum, serum, plasma, BAL, urine) and
imaging technologies that can accurately measure the rate of
disease progression are urgently needed. Furthermore, the ma-
jority of preclinical data described in this review has been
generated in 2D submerged single cell culture systems or an-
imal models. To build preclinical confidence, more advance
culture systems (ALI, 3D culture models) and ex vivo tissue
culture technique such as precision cut slices should be con-
sidered [243, 244]. Similarly, the use of primary human cells
isolated from diseased tissue is preferential when interrogating
mechanism of inflammation and fibrosis as there is a large
body of evidence to suggest that fibroblasts isolated from nor-
mal and fibrotic tissue behave differently in culture
[245–248].
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